02171 CARSGEN-B
- 6.650
- +0.220+3.42%
CARSGEN-B News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Keji Pharmaceutical-B (02171) grants 260,000 share options and 60,000 restricted share units
Keji Pharmaceutical-B (02171) issued an announcement. On May 7, 2024, the company purchased after sales in accordance with the initial public offering...
Keji Pharmaceutical-B (02171.HK) received an increase of 815,000 common shares by Guo Huaqing, worth approximately HK$4.832,900
On May 7, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 7, Guo Huaqing increased his shares of $Keji Pharmaceutical-B (02171.HK) by $815,000 at an average price of HK$5.9299 per share on April 30, worth about HK$4.832,900. After the increase in holdings, Guo Huaqing's latest shareholding was 216 million shares, and the good position ratio increased from 37.45% to 37.59%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. upon
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Keji Pharmaceutical-B (02171): Abstracts of Sikaize and CT071 will be presented separately in oral presentations and posters at the upcoming 2024 EHA Annual Meeting
According to Zhitong Finance App News, Keji Pharmaceutical-B (02171) announced that abstracts of Saikaize (Zewokie Orense injection, product number: CT053, an autologous CAR-T product targeting BCMA) and CT071 (an autologous CAR-T cell candidate product targeting G protein-coupled receptor C group 5 member D (GPRC5D)) have been received for separate oral reports and poster presentations at the 29th European Association of Hematology (EHA) Annual Meeting. According to reports, Cykaize is a whole-person anti-autologous BCMA CAR-T for the treatment of recurrent or refractory multiple myeloma
CARsgen Submitted Responses to FDA Observations
SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancie
Keji Pharmaceutical-B (02171.HK): Submission of a rectification report on FDA findings
Gelonghui, April 29 | Keji Pharmaceutical-B (02171.HK) issued an announcement. The rectification report on the Corrective and Preventive Measures (CAPAs) plan has been submitted to the US Food and Drug Administration (FDA). This submission relates to findings in Form 483 issued by the FDA after an inspection of the clinical production site in Tulham, North Carolina in December 2023. The relevant work is progressing smoothly according to the schedule previously submitted. The company promises to work closely with the FDA to prioritize quality and ensure the production of clinical trial products.
Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171.HK) rose by more than 11% CT053 commercialized and implemented CT041 research results to be unveiled in 2024 ASCO
Keji Pharmaceutical-B (02171.HK) rose by more than 11% during the day. As of press release, it rose 5.54% to HK$5.33, with a turnover of HK$9.66,200.
Keji Pharmaceutical-B (02171.HK): CT053 commercialization implementation looks forward to overseas breakthroughs
CT053, the main investment point, has been successfully commercialized, and the CT041 phase II is being promoted domestically, and we are looking forward to the NDA. We are optimistic that the company is a leading global solid tumor CAR-T company, and its CT053, CT041 and other pipelines are successive
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
科濟藥業-B：二零二三年年度報告
The CAR-T market is approaching 100 billion dollars: domestic companies ensure “survival”, and multinational companies earn dollars
On March 1 of this year, Keji Pharmaceutical-B (02171)'s CAR-T therapy Zewokie Orense injection (SAKIZE) was officially approved for sale, and the number of CAR-T treatments marketed worldwide has also reached 11. Although some of these products compete with each other in terms of treatment of indications, the rapid growth in sales of leading products is still driving the rapid expansion of the global market. The Zhitong Finance App learned that the global CAR-T cell therapy market is expected to reach US$88.52 billion in 2032. The 100 billion dollar market is in sight, and it continues to boost the market's investment confidence. However, not every product
Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171.HK) fell sharply by more than 16%. The company lost 748 million yuan in 23 and narrowed 16.19% year-on-year
Keji Pharmaceutical-B (02171.HK) fell sharply by more than 16%. At press time, it fell 16.78% to HK$4.77, with a turnover of HK$4.3 million.
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024
Carsgen Therapeutics Holdings (HKG:2171) said it will give an oral presentation of satricabtagene autoleucel on June 3 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, accordin
Featured announcements | Shandong Gold's Q1 net profit is expected to increase by 48.11% to 70.9% year-on-year
Xinji Shaxi: 14.16% of the company's shares held by the controlling shareholder were forcibly sold, and trading resumed today; express sales: net profit of 195.9 billion yen in the first half of the year, up 27.7% year on year; Smore International: profit after tax for the first quarter was about 339.5 million yuan, up 12.8% year on year.
Keji Pharmaceutical-B (02171.HK): CT041 abstracts were accepted for oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting
Keji Pharmaceutical-B (02171.HK) issued an announcement. The company's board of directors announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received for an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Keji Pharmaceutical-B (02171.HK) made an oral report on the CT041 test data update at the 2024 ASCO Annual Meeting
Gelonghui, April 11 | Keji Pharmaceutical-B (02171.HK) announced that the abstract of CT041 (a candidate product targeting Claudin18.2 autologous CAR-T cells) has been received as an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. CT041 is a potentially world-first autologous CAR-T cell candidate targeting Claudin18.2 protein. It is used to treat Claudin18.2 positive solid tumors, mainly gastric cancer/esophagastric junction adenocarcinoma and pancreatic cancer. Ongoing trials are included
Keji Pharmaceutical (2171.HK): Seckaize has been approved for marketing and commercial release can be expected
Guide to this report: Sikaize was approved for listing. Huadong Pharmaceutical helped commercialize it. CT041 treatment for gastric cancer of at least 3L is expected to submit an NDA by the end of this year. It is optimistic about the company's long-term development and maintains an “increase” rating. Summary: Maintaining “Accumulation”
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Analysis
Price Target
No Data
